

Current Status: Active PolicyStat ID: 8554854



 Origination:
 4/10/2020

 Last Approved:
 9/8/2020

 Last Revised:
 9/4/2020

 Next Review:
 9/8/2023

Owner: Jason Arimura: Director-

Pharmacy Services

Policy Area: COVID-19

References:

Initiating Medication Therapy to Treat COVID-19 Infections

Purpose:

This guideline ensures a safe and standardized approach to initiating medication therapies to treat COVID-19 infections.

Procedure:

When the patient care team determines that medication therapy is desired to treat COVID-19 infection, the following steps shall be followed:

- A. Contact the Infectious Disease team.
 - 1. All medications that are ordered with the purpose of treating COVID-19 infection are restricted and required approval from the Infectious Disease team. These medications include:
 - a. Remdesivir
 - b. Tocilizumab
 - 2. No doses shall be dispensed from the pharmacy until there is approval from the Infectious Disease team.
- B. If the Infectious Disease team approves the use of medication therapy for treatment of COVID-19 infection, obtain patient consent using *Attachment A & B Patient Consent Form for COVID-19 Treatment*.
 - 1. If remdesivir is used for COVID-19 treatment, provide a copy of *Attachment C & D Remdesivir Fact Sheet* to the patient.
- C. Once the *Patient Consent Form for COVID-19 Treatment* is completed, an order for the desired medication therapy may be submitted for pharmacy review.
- D. Refer to Attachment E VCMC & SPH Management Guidelines for COVID-19 management guidelines.

All revision dates:

9/4/2020, 5/20/2020, 4/10/2020

Attachments

Attachment A Patient Consent Form For COVID-19 Treatment (English)

Attachment B Patient Consent Form For COVID-19 Treatment (Spanish)

Attachment C Remdesivir Fact Sheet (English)

Attachment D Remdesivir Fact Sheet (Spanish)

Attachment E VCMC & SPH COVID-19 Management Guidelines

Approval Signatures

Step Description	Approver	Date
PolicyStat Administrator	Jason Arimura: Director-Pharmacy Services	9/8/2020
Policy Owner	Jason Arimura: Director-Pharmacy Services	9/8/2020

